decisionhealth Newsletters, Part B News - 2006 Issue 3 (March)
You're overpaid for a lot of ASP drugs, OIG charges
Subscribe or sign in to view the full article.
Article Overview
This article reviews an OIG assessment of Medicare drug reimbursement under the average sales price methodology and explains why the issue matters for providers, suppliers, and manufacturers. It discusses the reported impact on Medicare payment accuracy, the types of drugs affected, and the broader policy implications for HCPCS drug pricing.
Why This Topic Matters
The topic is relevant to readers who monitor Medicare Part B drug reimbursement, ASP-based pricing, and OIG/CMS payment policy updates. It highlights a reimbursement methodology issue that can affect payment accuracy and financial outcomes for multiple stakeholders.
What You Will Learn
- How the article frames an OIG review of Medicare drug reimbursement under ASP-based pricing.
- What kinds of payment impact the report says were identified across drug HCPCS codes.
- Why the article says drugs with multiple manufacturers are central to the issue.
- Which stakeholders the article suggests may be affected by the pricing findings.
Who Should Read This
- Medical coders
- Billers
- Revenue cycle professionals
- Physician practices
- Pharmacy reimbursement staff
- Healthcare administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com